SCHEMBL5652444

SCHEMBL5652444

COCCOc1cc2ncc(C#N)c(Nc3cc(OC)c(Cl)cc3OC)c2cc1OC

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 20/20 0.89
ABL1 P00519 6/20 0.74
BCR P11274 4/20 0.74
KCNH2 Q12809 2/20 0.67
CYP3A4 P08684 1/20 0.67
CYP2D6 P10635 1/20 0.67
CYP2C9 P11712 1/20 0.67
ABL2 P42684 3/20 0.66
STK25 O00506 1/20 0.66
CIT O14578 1/20 0.66
RIOK3 O14730 1/20 0.66
MAP2K7 O14733 1/20 0.66
CHEK1 O14757 1/20 0.66
CASK O14936 1/20 0.66
GAK O14976 1/20 0.66
EPHB6 O15197 1/20 0.66
MAP3K13 O43283 1/20 0.66
MAP3K7 O43318 1/20 0.66
RIPK2 O43353 1/20 0.66
NUAK1 O60285 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6182533 0.94 SRC (1.00) SRCABL1BCRKCNH2CYP3A4
SCHEMBL6182900 0.90 SRC (0.93) SRCABL1BCRKCNH2CYP3A4
SCHEMBL6182389 0.89 SRC (0.91) SRCABL1BCRKCNH2CYP3A4
SCHEMBL6186881 0.88 SRC (0.85) SRCABL1BCRKCNH2CYP3A4
SCHEMBL6184168 0.87 SRC (1.00) SRCABL1BCRABL2EGFR
SCHEMBL5651176 0.87 SRC (0.76) SRCABL1BCRKCNH2CYP3A4
SCHEMBL29618203 0.86 SRC (0.85) SRCABL1BCRKCNH2CYP3A4
SCHEMBL2886333 0.86 SRC (0.85) SRCABL1BCRKCNH2CYP3A4
SCHEMBL6185458 0.86 SRC (0.86) SRCABL1BCRKCNH2CYP3A4
SCHEMBL6183244 0.86 SRC (0.85) SRCABL1BCRABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299092-A1 Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors WYETH (US) 2007-12-27 US disclosed
WO-2005115145-A2 QUINONE SUBSTITUTED QUINAZOLINE AND QUINOLINE KINASE INHIBITORS WYETH (US) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299092-A1 Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors KDR, FLT1, FLT4 SRC 960/4885ABL1 64/4885BCR 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.